The CRISPR and Cas gene market size is expected to grow from US$ 4.13 billion in 2024 to US$ 18.04 billion by 2031; it is projected to register a CAGR of 23.4% during 2025-2031. The rising prevalence of genetic disorders, growing research funding and investments, and surging demand for precision medicine are noteworthy factors contributing to the expansion of the CRISPR and Cas gene market size. Additionally, the evolution toward next-gen editing is projected to bring new CRISPR and Cas gene market trends in the near future.

The CRISPR-Cas gene editing landscape is evolving beyond traditional Cas9 nucleases. Next-generation tools such as base editing, prime editing, and RNA/epigenetic editing offer precision without such risks, driving therapeutic breakthroughs. These techniques can fix 90% of known disease-causing mutations. Base editing, pioneered by David Liu's lab, fuses a deactivated Cas9 with deaminases to convert C?G to T?A or A?T to G?C base pairs. Beam Therapeutics employs base editors to target SCD, achieving up to 80% correction efficiency in hematopoietic stem cells with minimal indels.

Prime editing combines the use of the Cas9 nickase with a reverse transcriptase and a prime editing guide RNA (pegRNA) to enable "search-and-replace" modification, such as insertions and deletions, of a DNA span extending to 44 bp. In 2020, Prime Medicine's technology demonstrated functional correction within patient organoids for the treatment of cystic fibrosis. In February 2025, it carried out first-in-human prime editing in a rare metabolic disorder and showed a modification efficiency ranging between 50%-70%. As of April 2025, there are 98 clinical trials based on these modalities that foretell a new age of safe and versatile gene therapies. The next generation of gene-editing technologies signals a paradigm shift within the CRISPR area. These innovations promise safer, more versatile therapies for genetic diseases, cancer, and infectious disorders, thereby emerging as a significant trend in the CRISPR and Cas gene market.

End User-Based Insights

Based on end user, the CRISPR and Cas gene market is segmented into biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations and CDMOs. The biotechnology and pharmaceutical companies segment held the largest CRISPR and Cas gene market share in 2024. The growth in this segment is driven by their massive investments in clinical development, partnerships, and commercialization to unlock new therapies using CRISPR. One such example is the collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics to create Casgevy (exagamglogene autotemcel), marking the first FDA-approved CRISPR-mediated approach to treating sickle cell disease and transfusion-dependent beta-thalassemia. This approach offers long-term patient benefits by precisely editing hematopoietic stem cells. Similarly, companies like Intellia Therapeutics moved their candidate, NTLA-2002, a CRISPR-based in vivo approach for hereditary angioedema, to a Phase 3 clinical trial in 2025, with encouraging reductions in attack rates. Other examples include Verve Therapeutics and their CTX-310 candidate, which aims to reduce LDL cholesterol and triglycerides by targeting ANGPTL3, with promising phase 1 clinical trial data expected in 2025. This increase in clinical trials and approval highlights that this segment is also witnessing growth driven by their huge requirements for personalized healthcare, increasing incidence rates for genetic disorders, and appropriate acquisition to improve CRISPR technology, making biotech and pharma giants leaders in next-generation gene therapies, thereby fueling the CRISPR and Cas gene market growth.

The World Health Organization and the FDA are among the primary and secondary sources referred to while preparing the CRISPR and Cas gene market report.